Copertina

Two-year follow-up for oncological, functional, and quality-of-life outcomes in the randomized ROBOCOP II trial of robot-assisted versus conventional open partial nephrectomy

Background and objective - Robot-assisted partial nephrectomy (RAPN) is increasingly used to treat renal cell carcinoma (RCC), but randomized data comparing long-term outcomes to those after open partial nephrectomy (OPN) remain limited. Our aim was to compare oncological, renal function, and health...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Haney, Caelán Max (Autore) , Gottstein, Luise (Autore) , Sidoti Abate, Marie Angela (Autore) , Menold, Hanna Saskia (Autore) , Fattal, Mohamad Wahid (Autore) , Neuberger, Manuel (Autore) , Nuhn, Philipp (Autore) , Westhoff, Niklas Christian (Autore) , Honeck, Patrick (Autore) , Michel, Maurice Stephan (Autore) , Kriegmair, Maximilian (Autore) , Kowalewski, Karl-Friedrich (Autore)
Natura: Article (Journal)
Lingua:inglese
Pubblicazione: June 2026
In: European urology focus
Year: 2026, Volume: 12, Fascicolo: 3, Pages: 436-443
ISSN:2405-4569
DOI:10.1016/j.euf.2026.02.003
Accesso online:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.euf.2026.02.003
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2405456926000295
Testo
Note sull'autore:Caelán Max Haney-Aubert, Luise Gottstein, Marie Angela Sidoti Abate, Hanna Saskia Menold, Wahid Fattal, Manuel Neuberger, Philipp Nuhn, Niklas Westhoff, Patrick Honeck, Maurice-Stephan Michel, Maximilian Christian Kriegmair, Karl-Friedrich Kowalewski
Descrizione
Riassunto:Background and objective - Robot-assisted partial nephrectomy (RAPN) is increasingly used to treat renal cell carcinoma (RCC), but randomized data comparing long-term outcomes to those after open partial nephrectomy (OPN) remain limited. Our aim was to compare oncological, renal function, and health-related quality of life (HRQOL) outcomes at 2 yr for patients who underwent RAPN versus OPN. - Methods - This single-center phase 2 randomized controlled trial included 50 patients with suspected localized RCC who were randomized 1:1 to RAPN or OPN. After 2-yr follow-up, we assessed overall survival (OS), recurrence-free survival, renal function, and HRQOL, including chronic postoperative pain and flank bulge. Analyses were conducted on an intention-to-treat basis. - Key findings and limitations - All but one patient completed oncological and renal follow-up, and 47 provided HRQOL data. At 2 yr, overall survival was 100%, with one lymph-node recurrence in the RAPN group. The adjusted mean estimated glomerular filtration rate did not differ between the groups (OPN 74.1 ml/min/1.73 m2, 95% confidence interval [CI] 69.7-78.5; RAPN 75.8 ml/min/1.73 m2, 95% CI 71.3-80.1; p = 0.59). HRQOL at 2 yr remained high, with no significant difference in changes from baseline between the two groups. Chronic postoperative pain at the operative site (44% vs 0%; p = 0.001) and flank bulge (32% vs 0%; p = 0.007) were significantly more common in the OPN group versus the RAPN group. - Conclusions and clinical implications - RAPN and OPN yielded excellent long-term outcomes. RAPN offers advantages in terms of postoperative morbidity without compromising renal function or QOL.
Descrizione del documento:Online verfügbar: 27. Februar 2026, Artikelversion: 31. Juli 2026
Gesehen am 24.08.2026
Descrizione fisica:Online Resource
ISSN:2405-4569
DOI:10.1016/j.euf.2026.02.003

Documenti analoghi